Chesapeake Corp

Chesapeake — Investor Presentation (September 2007)

40 slides from Chesapeake's investor presentation, Sep 11, 2007

  1. Slide 1: Investing In Chesapeake

    Exhibit 99.1 Investing In Chesapeake 1 September 2007

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause Chesapeake's ac

  3. Slide 3: Chesapeake's Objective

    Chesapeake’s Objective Build a sustainable competitive advantage through • Rationalizing our costs • Expanding in developing markets • Capitalizing on our outstanding customer base 3

  4. Slide 4: Chesapeake History & Strategic Transformation

    Chesapeake History & Strategic Transformation • Founded in 1918 in West Point, Virginia as a kraft pulp and paper mill and listed on the NYSE since 1944 • Initiated a strategic transformation in the mid-1990s to become a leading global supplier of value-added specialty packaging products Boxmore Int

  5. Slide 5: Chesapeake Today

    Chesapeake Today • Leading supplier of value-added specialty packaging in chosen markets – Paperboard • Pharmaceutical • Alcoholic Drinks, Confectionery & Tobacco – Plastics • Specialty Chemicals • Irish Dairy • African Beverage • Strong reputation for design and innovation • Growing presence in Eas

  6. Slide 6: Chesapeake at a Glance

    Chesapeake at a Glance Pharma Branded Specialty Plastics 2006 $410 million $430 million $155 million Revenue • European Specialty Chemicals Leading Market • European Pharma Cartons • European Drinks Cartons Positions • North American Leaflets • European Confectionery • Irish Dairy • Sub-Saharan Afri

  7. Slide 7: Blue-Chip Customer Base

    Blue-Chip Customer Base Pharmaceuticals Branded Products Specialty Plastics 7

  8. Slide 8: Paperboard Products

    Paperboard Products <a Chesapeake

  9. Slide 9: Specialty Plastics Products

    Specialty Plastics Products 9

  10. Slide 10: Global Manufacturing Capabilities

    Global Manufacturing Capabilities United States China Europe Pharmaceuticals and Healthcare Branded Products Specialty Plastic Packaging South Africa & Mauritius 10

  11. Slide 11: Paper-Based Packaging in Western Europe

    Paper-Based Packaging in Western Europe Leading Western European Carton Converters ($mm sales) Mayr-Melnhof Chesapeake MeadWestvaco Nampak Van Genechten A&R Carton Amcor Rentsch Edelmann Gruppe Graphic Packaging 0 200 400 600 800 Source: Packaging Focus 2006 11

  12. Slide 12: A Leading Supplier to the Global Pharmaceutical Industry

    A Leading Supplier to the Global Pharmaceutical Industry A leading paper-based packaging supplier to the European pharmaceutical market • Leading full-service supplier of printed materials in Europe Chesapeake 17% significant trading positions with 9 of the top 10 global pharmaceutical companies • L

  13. Slide 13: Business Overview

    Business Overview 8 (C Chesapeake’

  14. Slide 14: Pharmaceutical & Healthcare Market

    Pharmaceutical & Healthcare Market Key Demand Drivers: Customer Requirements/Needs: • Increasing use of lifestyle • Comprehensive design services drugs • Special packaging features • Aging population • Reduced delivery times • Increasing OTC drug sales • Flexibility in order size • Information discl

  15. Slide 15: Pharmaceutical Products

    Pharmaceutical Products • 26 Facilities across 11 countries • Carton, Label, and Leaflet production capabilities for: Prescription medicines (ethical and generic) Over-the-counter medicines Healthcare products such as vitamins and contact lens solutions Medical devices Quasi-medicinal products such

  16. Slide 16: Branded Products Market

    Branded Products Market Key Demand Drivers: Customer Requirements/Needs: • Increased consumer • Brand positioning/differentiation marketing focus on in discerning global markets promotional packaging • Multi-substrate capabilities • Greater demand for anti- • Consistent image/anti- counterfeiting as

  17. Slide 17: Branded Products

    Branded Products • 14 Locations—U.K., Germany, Spain • Carton, Label and Film production capabilities for: – Alcoholic beverage boxes (paper-based or composite) – Tobacco packaging – Confectionery – Multi-substrate designs • Dedicated design center in Bradford, U.K. • Technology to produce unique, s

  18. Slide 18: Specialty Plastics Market

    Specialty Plastics Market Key Demand Drivers: Customer Requirements/Needs: • Increased soft drink and • Lighter weight containers for mineral water consumption agrochemicals and other specialty chemicals with superior barrier • Barrier containers for characteristics agrochemicals and other • Innovat

  19. Slide 19: Specialty Plastics Products

    Specialty Plastics Products • 8 Facilities across 7 countries • Design and manufacture of HDPE bottles, closures & containers and PET bottles, closures, containers & preforms for: – Agrochemical and other specialty chemicals – Food and beverages • Proprietary in-line flourinated barrier technology t

  20. Slide 20: Chesapeake's Strategy

    Chesapeake’s Strategy • Expand pharmaceutical and healthcare business geographically Continued Growth in — Eastern Europe, Asia and North America Pharma • Further penetration of pharmaceutical market with additional Market leaflet and label capacity • Leverage existing end-markets success to expand

  21. Slide 21: Growth Initiatives

    Growth Initiatives The Company is seeking to develop business in new and emerging markets and will capitalize on its ability to deliver products with consistent quality across continents Asia-Pacific • New pharmaceutical packaging plant near Shanghai, China complete – start-up late 2007 • Unique pro

  22. Slide 22: Chesapeake's Strategy

    Chesapeake’s Strategy Dedicated teams to address changing market dynamics and provide innovative packaging solutions – anticounterfeiting – Braille Product & – knowledge of innovative substrates Service Multi-layer PET preform technology for sub-Saharan African customers to maximize their Innovation

  23. Slide 23: Historical Financial Summary

    Historical Financial Summary 23

  24. Slide 24: Key Financial Highlights

    Key Financial Highlights • CSK financial performance from 2002 - 2004 – Reported revenue, gross profit and Adjusted EBITDA increased annually – Cash flow from operations increased at a 35% CAGR – Debt was reduced by $ 62.5 million • Financial performance has declined in 2005 and 2006 – The decline i

  25. Slide 25: #1 Focus is to Increase Cash Flow & Profitability

    #1 Focus is to Increase Cash Flow & Profitability Cost Savings Program - $25 million Proactive Management of Pension Obligations Organic Growth - Worldwide pharmaceutical packaging demand expected to grow 5% per year to 2009, CSK position with top 20 Pharmaceutical customers Increased Cash Flow Stra

  26. Slide 26: Reported Historical Financial Summary

    Reported Historical Financial Summary ($ in Millions, except per share) Fiscal Year End 2002 2003 2004 2005 2006 Total Net Sales $ 755.6 $ 850.4 $ 997.9 $ 1,009.2 $ 995.4 % Growth n/a 12.5% 17.3% 1.1% -1.4% Adjusted EBITDA 107.6 110.3 111.5 106.0 101.3 % Margin 14.2% 13.0% 11.2% 10.5% 10.2% Adjusted

  27. Slide 27: Paperboard Segment

    Paperboard Segment ($ in Millions) Revenue Adjusted EBITDA $1,000.0 $120.0 $830.9 $827.4 $840.4 $103.6 $101.6 $98.2 $718.2 $91.3 $750.0 $80.0 $500.0 $40.0 $250.0 $0.0 $0.0 2003 2004 2005 2006 2003 2004 2005 2006 Based on 2003 exchange rates FX Impact Based on 2003 exchange rates FX Impact Adjusted E

  28. Slide 28: Plastics Segment

    Plastics Segment ($ in Millions) Revenue Adjusted EBITDA $200.0 $30.0 $181.8 $26.0 $25.7 $167.0 $24.6 $155.0 $22.6 $150.0 $132.2 $20.0 $100.0 $10.0 $50.0 $0.0 $0.0 2003 2004 2005 2006 2003 2004 2005 2006 Based on 2003 exchange rates FX Impact Based on 2003 exchange rates FX Impact Adjusted EBITDA is

  29. Slide 29: Normalized Performance

    Normalized Performance ($ in Millions) Fiscal Years Ended 2003 2004 2005 2006 Adjusted EBITDA $ 110.3 $ 111.5 $ 106.0 $ 101.3 Foreign exchange impact (12.8) (12.2) (11.3) Pension increase over 2003 4.2 9.2 16.0 Normalized Adjusted EBITDA $ 110.3 $ 102.9 $ 103.0 $ 106.0 Normalized Adjusted EBITDA is

  30. Slide 30: 2007 Half Year Financial Update

    2007 Half Year Financial Update • Adjusted operating income up $3.2 million versus first half 2006 • Continue to believe 2007 operating income will show improvement over last year, despite significant reduction in British American Tobacco packaging volumes • Cost savings program expected to exceed g

  31. Slide 31: $25-Million Cost Savings Program

    $25-Million Cost Savings Program 31

  32. Slide 32: Cost Savings Program

    Cost Savings Program • $25-million annual cost savings initiative announced Q4 2005 – Two year implementation period: 2006 - 2007 – Estimated cost of $30 - $40 million pre-tax • Sale or closure of underperforming / underutilized assets • General workforce reduction • Process improvement and overhead

  33. Slide 33: Cost Savings Program

    Cost Savings Program Significant accomplishments through June 2007 • Initiatives implemented as of March 2007 expected to achieve $25m in annualized savings • Completed 3 plant closures • Sold 2 underperforming businesses • Total workforce reduction 600+ (10%) • Cash cost of $26m offset by asset sal

  34. Slide 34: Proactive Management of Pension Obligations

    Proactive Management of Pension Obligations • Proactive management of obligations – US Plan benefits frozen 12/05, UK Plan closed to new entrants 12/05 – Reduced UK benefits level for new entrants in 2004 – Increased UK employer and employee contribution rates in 2004 • Rising discount rates reduce

  35. Slide 35: Pension & OPEB Net Funded Status

    Pension & OPEB Net Funded Status ($ in millions) $ 150 All 120 qualified pension 90 plans expected 60 to exceed 90% 30 funding in 0 2007. 2003 2004 2005 2006 35

  36. Slide 36: #1 Focus is to Increase Cash Flow & Profitability

    #1 Focus is to Increase Cash Flow & Profitability Cost Savings Program - $25 million Proactive Management of Pension Obligations Organic Growth - Worldwide pharmaceutical packaging demand expected to grow 5% per year to 2009, CSK position with top 20 Pharmaceutical customers Increased Cash Flow Stra

  37. Slide 37: Appendix

    =e Appendix (C Chesapeake’

  38. Slide 38: Financial Reconciliations

    Financial Reconciliations Reconciliation of Adjusted EBITDA and Adjusted Operating Income to Operating Income ($ in Millions) Year-Ended December 29, December 28, January 2, January 1, December 31, 2002 2003 2005 2006 2006 Sales from continuing operations: Paperboard Packaging $651.9 $718.2 $830.9 $

  39. Slide 39: Financial Reconciliations

    Financial Reconciliations Reconciliation of Adjusted EPS to Diluted EPS from Continuing Operations Year-Ended December 29, December 28, January 2, January 1, December 31, 2002 2003 2005 2006 2006 Adjusted EPS $ 1.03 $ 1.08 $ 0.91 $ 0.88 $ 0.36 Goodwill impairment charge (16.07) (0.74) Restructuring

  40. Slide 40: Investing In Chesapeake

    Investing In Chesapeake 40 September 2007

Chesapeake — Investor Presentation (September 2007) on 6ix